When joint replacement is not your only option

Being told that knee replacement is 'probably coming' is a specific kind of conversation — and for many patients, it arrives earlier than they expected. What often goes unsaid in that consultation is that joint replacement is not the only remaining pathway, and that the timing matters enormously.

ChondroFiller — also known as Liquid Cartilage — is a CE-marked Class III medical device: an injectable collagen scaffold placed into the damaged area of the joint under ultrasound guidance, as an outpatient appointment. It is not a painkiller, and it is not a lubricating fluid. It works by providing a structural matrix that recruits the joint's own progenitor cells to support repair of the damaged tissue — a process called acellular matrix-induced chondrogenesis.

For patients who still have meaningful residual joint architecture, this approach sits earlier on the treatment pathway than replacement, and the published evidence suggests it may delay or reduce the need for surgery in suitable candidates. That is a meaningfully different offer from symptom management alone.

Candidacy matters, though. ChondroFiller is not a substitute for joint replacement in an end-stage, bone-on-bone knee where the structural basis for repair no longer exists. The sections that follow set out the mechanism, who tends to benefit, and what the clinical evidence actually shows.

How the injectable collagen scaffold works

The collagen preparation arrives at the joint as a liquid, mixed at the point of delivery through a two-chamber syringe. Within 3–5 minutes of placement under ultrasound guidance, it cures into a porous hydrogel that conforms precisely to the defect geometry and adheres to the surrounding cartilage surface.

That porosity is the functional point. Unlike a solid filler, the cured scaffold has an open lattice structure that allows the joint's own progenitor cells — drawn from the adjacent synovium and subchondral bone — to migrate inward, proliferate, and begin producing new cartilage matrix. The implant itself contains no cells; it supplies the structural architecture that makes the body's own repair response possible.

This places ChondroFiller in a different category from three treatment types patients commonly encounter. Hyaluronic acid viscosupplementation functions as a lubricant within the joint fluid — it does not repair tissue. Arthrosamid (a polyacrylamide hydrogel) is a permanent, non-biodegradable cushion injected into the synovium, providing mechanical padding rather than structural regeneration. ACI and MACI — autologous chondrocyte implantation techniques — require two surgical stages and laboratory cell culture before any material is placed. ChondroFiller is a single-step, acellular, injectable scaffold pathway.

One practical consequence of how the scaffold works is that it needs time to stabilise before full joint loading resumes. A 2024 in-vitro biomechanical study found that the cured gel does not immediately provide full mechanical protection to opposing cartilage surfaces — and it is this finding that gives the graduated weight-bearing protocol its clinical rationale.

Which patients are most likely to benefit

Two quite different joint profiles may be suitable for ChondroFiller, and understanding which category applies is the starting point for any realistic self-assessment.

The classic candidate has a focal, isolated chondral defect — typically Grade III or IV cartilage damage confined to an area up to roughly 4–6 cm², with intact surrounding cartilage borders. This profile most often fits an active or younger patient who has sustained a discrete injury rather than accumulated generalised wear. The 12-month Bulgarian cohort that tracked Lysholm and IKDC outcomes had a mean patient age of 31, reflecting this core demographic.

Age alone, however, is not an exclusion. The indication has expanded materially, and for patients with diffuse, advanced osteoarthritis at Kellgren-Lawrence Grade III or IV, combination protocols have been developed that pair ChondroFiller with adjunct agents addressing different aspects of the joint environment — the regenerative scaffold targeting the structural deficit, and a separate component targeting the synovial space through a distinct mechanism. These protocols are assessed case by case; a single-product pathway may not be sufficient for widespread joint degeneration.

Where ChondroFiller is unlikely to be the answer is in a knee that has reached true end-stage disease — significant structural bone loss, severe joint-space collapse, or bone-on-bone contact throughout the compartment. At that point, the structural basis that a scaffold requires no longer exists, and joint replacement becomes the more appropriate conversation.

Determining which of these scenarios applies requires weight-bearing imaging and a detailed review of joint architecture. Candidacy cannot be established from symptoms alone.

What the clinical evidence shows

Three published studies form the core of the current evidence. In a prospective randomised multicentre trial comparing ChondroFiller directly with microfracture — the standard surgical approach for focal cartilage defects — IKDC patient-reported scores improved significantly from pre-operative baseline at three and six months (p<0.05), with that improvement maintained at 12 months. MRI assessed using the MOCART scoring system confirmed good immediate defect filling and progressive scaffold maturation across the full 52-week observation period, and no adverse events were recorded in the ChondroFiller group.

The 12-month prospective cohort added a separate measure of durability: both Lysholm and IKDC scores were statistically significantly improved at every assessment point through 12 months (p<0.05), with no meaningful difference between the six- and 12-month readings (p>0.05). That stable plateau between six and 12 months is the more informative signal — it indicates that the functional gain had held rather than faded as the scaffold continued to mature.

Pooling across the published evidence, roughly 70–85% of patients treated within the classic candidacy criteria — focal defects up to 4–6 cm² with intact surrounding cartilage borders — report meaningful symptom relief at three to five years, a figure that is consistent across knee, hip, and small-joint applications. That range uses the focal-defect profile as its denominator; outcomes in more advanced disease depend heavily on which combination protocol is used and are still being characterised.

Evidence is also emerging for wider application. A 2025 prospective controlled trial recruited patients with Kellgren-Lawrence Grade IV knee osteoarthritis and paired ChondroFiller with a blood-derived stem cell-rich graft — extending the indication into disease severity that had previously sat outside the standard focal-defect profile.

What the evidence does not yet confirm is worth stating plainly: long-term randomised data comparing ChondroFiller injection directly with total knee replacement is limited, and most published studies are small prospective controlled trials rather than large double-blind RCTs. That is not atypical for a CE-marked Class III orthopaedic device — CE marking is the applicable regulatory standard for the UK and Europe; ChondroFiller does not hold FDA approval — but it does mean individual outcome predictions should rest on a proper clinical assessment rather than on population-level statistics alone.

Combination pathways for advanced or diffuse OA

When Kellgren-Lawrence Grade III or IV imaging indicates that cartilage loss is diffuse rather than focal, a single scaffold injection may not be sufficient on its own. The clinical reasoning for combining ChondroFiller with a second injectable agent in such cases comes down to matching each product to the problem it is best placed to address: the collagen scaffold targets the structural cartilage deficit, while a separate agent — in the dual-injection protocol, Arthrosamid — addresses the synovial environment through an entirely different mechanism. The two products work in parallel on distinct aspects of the same joint problem and should not be collapsed into a single category.

For patients whose disease is more advanced still — or where cartilage loss is accompanied by a compromised biological repair environment — some assessments lead to a protocol that incorporates autologous mesenchymal stem cells alongside the scaffold and cushioning agent. This is not a standard first-line approach; it is reserved for presentations where the treating specialist judges that the cellular environment itself needs augmentation and where the complexity of an intensive protocol is clinically warranted.

For patients who respond well to initial treatment, a structured monitoring programme built around periodic scaffold top-up injections and regular MRI review can form the basis of a longer-term joint-preservation strategy. The aim is to sustain the structural benefit rather than waiting for symptoms to deteriorate before any further intervention.

Combination protocols carry meaningfully higher guide costs than a single-product pathway, and the appropriateness of each element — scaffold alone, dual injection, or a more intensive approach with cellular augmentation — depends on imaging, clinical history, and detailed specialist assessment. Individual suitability cannot be determined from symptom severity alone.

Private access, guide costs, and booking an assessment

ChondroFiller is not available through the NHS and is delivered as a private treatment in the UK. Guide costs for a single-treatment pathway start at approximately £3,000, inclusive of clinical consultation, imaging review, the injectable scaffold product, and a six-week follow-up appointment; exact costs depend on the joint involved and whether a combination protocol is indicated, and are confirmed at assessment. Patients considering a first appointment can find further information and request an assessment at londoncartilage.com.

The outpatient injectable scaffold approach is joint-agnostic. While the knee accounts for the majority of referrals, the same pathway is documented across the hip, shoulder, ankle, and smaller joints — a point worth noting for patients whose primary concern falls outside the knee.

Arriving at a first consultation with weight-bearing imaging and a clear account of symptom history allows the specialist to move quickly to a structural evaluation. Useful questions to raise at any such appointment: the measured size and location of the defect on MRI, whether the surrounding cartilage borders appear intact, whether subchondral bone involvement is present, and whether the current degree of joint involvement points toward a standalone scaffold injection or a combination protocol. Those structural answers — not symptom severity alone — are what determine whether ChondroFiller represents a realistic and appropriate next step.

1. [1] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Use of an Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft — A Prospective Controlled Trial. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360
2. [2] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z